SenoRx Launches New Breast Device

Aliso Viejo, CA - SenoRx Inc., announced that it has made available a new 7-Gauge size probe for its recently launched Multi Imaging Modality breast biopsy device, EnCor. EnCor Probes were previously only available in a 10-Gauge size. Lloyd H. Malchow, president and CEO of SenoRx, commented, "The new 7-Gauge probe size offers customers who desire even larger tissue samples another choice and further broadens the market opportunity for EnCor." In addition, the company recently announced that numerous clinical sites in the U.S. have performed MRI-guided breast biopsies with EnCor.

SenoRx has installed 180 EnCor systems in healthcare institutions during the early phase of its 2005 full commercial product launch. EnCor fully commercially launched in November 2005.

EnCor is the first fully programmable, automated, multi-modality, modular breast biopsy system available and represents the next generation of technology in breast disease diagnosis. EnCor is the first Breast Biopsy System that offers the benefits of both open and closed tissue collection. SenoRx completed over 18,000 cases prior to full commercial launch of EnCor.

Over 1,000 healthcare institutions in the United States use at least one of five commercially available SenoRx products, which the company began fully marketing in 2002. SenoRx currently has an annualized revenue run rate of $23MM and had 2005 revenue of approximately $19.2MM. Additionally, SenoRx has two new 510(k) cleared products scheduled to launch in the next 18 months.

SOURCE: SenoRx Inc.